ClinicalTrials.gg
RecruitingNCT07525843PHN WBCUpdated Oct 16, 2026

A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study

An interventional study of Telemedicine-based resiliency-building intervention in Patient-Reported Outcome Measures (PROMs), Pragmatic Trial and Adolescent Congenital Heart Disease, sponsored by Carelon Research. Recruiting at 14 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Carelon Research · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 16, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The goal of this pragmatic clinical trial is to learn if the WE BEAT program, a 5-week group-based online wellbeing and skill-building program, can help teens with congenital heart disease (CHD) improve their ability to handle stress. The main question it aims to answer is if participants who receive the WE BEAT program become more resilient (the ability to bounce back from tough times or recover from something difficult) and have better quality of life compared to participants who receive usual care. The study also aims to learn if there are connections between participant-reported psychosocial data (such as resilience, feelings about one's life and one's physical, mental, and social wellbeing) and clinical outcomes.

Eligible participants who are 12-17-year-old will be in the study for about 6 months and be randomized to receive either the WE BEAT program or usual care. Following completion of the primary WE BEAT intervention at Week 5, intervention arm participants will be randomized to a single-session booster session (occurring at Week 18) vs no booster session. The booster session will be provided in a similar format to the WE BEAT program. A review of all modules/skills introduced in the program will be provided.

All participants will complete 4 sets of online surveys and give 3 hair/saliva samples at different timepoints. Some participants may volunteer to give optional urine and second saliva samples.

02

Conditions studied

  • Patient-Reported Outcome Measures (PROMs)
  • Pragmatic Trial
  • Adolescent Congenital Heart Disease
  • Resiliency-building Intervention
  • Resilience, Psychological
  • Telemedicine-Based Education

Keywords

  • WE BEAT
  • Well-Being Education Program
  • Adolescent CHD
  • Pragmatic Clinical Trial
  • Telemedicine
03

In context

Lead sponsor

Carelon Research is the lead sponsor of 59 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 12-17 years old
  • CHD of moderate or severe complexity (Class II/III, 2018 AHA/ACC ACHD, Table 4)
  • English or Spanish language proficiency
  • Receives cardiology care at a PHN or PHN auxiliary site
  • Parent or guardian and participant willing to comply with protocol and provide written/electronic and assent

Exclusion criteria

Exclusion Criteria:

  • CHD of mild or simple complexity (Class I, 2018 AHA/ACC ACHD, Table 4)
  • Prior heart transplant to treat CHD
  • Heart disease that is not classified as structural CHD (e.g., connective tissue disease, genetic cardiomyopathy, or acquired heart disease)
  • Cognitive or developmental conditions that limit program participation and/or ability to complete self-reported measures as determined by a primary cardiology clinician
  • Suicidality, homicidality, or psychosis in the past 12 months as per medical chart review, clinician report, or eligibility screening
  • Medically unable to participate (e.g., intubated, unable to respond verbally, active delirium)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
390 participants (estimated)

Study arms

  • No intervention
    Usual Care

    Usual Care arm used as a control

  • Experimental
    Intervention arm

    WE BEAT telemedicine intervention

    Behavioral: Telemedicine-based resiliency-building intervention

Interventions

  • BehavioralTelemedicine-based resiliency-building intervention

    Improving Access and Increasing Resilience through the WE BEAT Well-Being Education Program. The WE BEAT Well-Being Education Program was developed for pediatric patients with heart disease. The evidence-based components of the 5-module WE BEAT intervention are derived from cognitive behavioral theory, stress management and resiliency research, and behavioral intervention science across pediatric populations and adult heart disease. The five WE BEAT modules include: Well-being Education--Introduction, Breathe--Mindfulness and Relaxation-Based Skills, Energize--Positive Psychology Skills, Adjust--Cognitive Skills Training, and Thanks--Gratitude Practice. The objective is to foster positive psychological well-being and resilient outcomes in adolescents with CHD through a mental health promotion and prevention while providing access to safe, peer-to-peer community building. Through its group-based telemedicine delivery, the program aims to increase access to mental health care.

06

What researchers measure

Primary outcomes

  1. Connor-Davidson Resilience Scale (CD-RISC)

    Connor-Davidson Resilience Scale© (CD-RISC©) is a self-reported, unidimensional 5-point Likert scale measuring resilience. Total scores range from 0-40 with higher scores indicating greater resilience. It has been validated for use in children and adolescents across various countries.

    Time frame: from baseline to week 5 (immediately post-intervention).

Secondary outcomes

  1. Connor-Davidson Resilience Scale (CD-RISC)

    Connor-Davidson Resilience Scale© (CD-RISC©) is a self-reported, unidimensional 5-point Likert scale measuring resilience. Total scores range from 0-40 with higher scores indicating greater resilience. It has been validated for use in children and adolescents across various countries.

    Time frame: from baseline to Week 18, from baseline to week 30, from baseline to week 5 (for the subpopulation of participants with moderate to low baseline CD-RISC)

  2. NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Scales

    NIH Patient-Reported Outcomes Measurement Information System® (PROMIS®) Scales is a self-reported, 5-point Likert scales measuring depressive symptoms (8 items); anxiety (8 items); meaning and purpose in life (4 items); life satisfaction (4 items).The NIH PROMIS® Scales have been validated for use in children with chronic health conditions ages 8-17 years old.

    Time frame: from baseline to week 5, baseline to week 18, baseline to week 30

  3. Kessler-6 (K6)

    Kessler-6 (K6) is a self-reported, 5-point Likert scale measuring general distress. Total scores range from 0-24 with higher scores indicating more psychological distress.

    Time frame: from baseline to week 5, baseline to week 18, baseline to week 30

  4. PedsQL, Generic Core and Cardiac Module

    PedsQL, Generic Core and Cardiac Module is a self-reported; 5-point Likert scale measuring health-related quality of life (HRQOL). Scores will be transformed to a 0-100 scale with higher scores indicating more positive HRQOL. The PedsQL™ Generic Core is widely used and includes four domains: Physical, Emotional, Social, and School functioning. The PedsQL™ Cardiac Module is administered in addition to the PedsQL™ Generic Core to gather cardiac-specific constructs important to QOL. Subscales include: Heart Problems and Treatment (e.g., symptoms, medical interventions), Treatment Barriers (e.g., difficulty accessing care, adherence with treatment), Perceived Physical Appearance (e.g., concerns related to scars, body image), Treatment Anxiety (e.g., worries about medical procedures and hospital visits), Cognitive Problems (e.g., difficulties in concentrating, memory issues), and Communication (e.g., ability to discuss condition and treatment with others).

    Time frame: from baseline to week 5, baseline to week 18, baseline to week 30

  5. Life's Essential 8

    Life's Essential 8 is a self-reported scoring tool measuring lifestyle behaviors. Items include assessment of diet, sleep, physical activity, and nicotine use/exposure.

    Time frame: from baseline to week 5, baseline to week 18, baseline to week 30

  6. Multidimensional Scale of Perceived Social Support

    Multidimensional Scale of Perceived Social Support is a self-reported; 7-point Likert scale measuring perceived social support. Total score ranges from 1-7 with higher scores indicating more perceived social support. Subscales include: family subscale, friends subscale, and significant other subscale.

    Time frame: from baseline to week 5, baseline to week 18, baseline to week 30

  7. Self-Perceived Health Status

    Self-Perceived Health Status is a self-reported; linear analog scale. Subjectively perceived health status will be measured with a linear analogue scale ranging from the ''worst imaginable health state'' (score of 0) to the ''best imaginable health state'' (score of 100).

    Time frame: from baseline to week 5, baseline to week 18, baseline to week 30

  8. WE BEAT Survey

    WE BEAT Survey is a self-reported. An investigator-designed survey used to gather WE BEAT session and overall program ratings and acceptability, as well as feedback and ideas for program improvement.

    Time frame: Intervention Participant Report at Week 5

  9. Concentration of cortisone (biomarker of stress)

    Hair cortisone levels will be assayed from hair samples

    Time frame: baseline, week 5, and week 30

  10. Concentration of C-reactive protein (CRP) (biomarker of inflammation)

    Concentration of C-reactive protein will be assayed from saliva samples

    Time frame: baseline, week 5, and week 30

  11. Concentration of TNF-alpha (biomarker of inflammation)

    Concentration of TNF-alpha will be assayed from saliva samples

    Time frame: baseline, week 5, and week 30

  12. Concentration of IL-6 (biomarker of inflammation)

    Concentration of IL-6 will be assayed from saliva samples

    Time frame: baseline, week 5, and week 30

  13. Concentration of IL-8 (biomarker of inflammation)

    Concentration of IL-8 will be assayed from saliva samples

    Time frame: baseline, week 5, and week 30

  14. Biomarkers of aging

    epigenetic markers of aging (from genome-wide epigenetic profiling) will be assayed from saliva samples from all participants who opted to provide optional saliva for the study

    Time frame: baseline

07

Study locations

14 of 14 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — PUD (Public Use Datasets) are planned to be created at the end of the study

Supporting information: Study protocol

Time frame: Public Use Datasets will be created and posted within the time-limits required by NHLBI

Access criteria: Will be posted on the Web and available to general public

Data sharing details ↗ · www.pediatricheartnetwork.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Apr 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Apr 13, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Apr 2029
CompletionEst.
Jun 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Stanford School of Medicine · Stanford, United StatesNot yet recruiting→Recruiting
  • Washington University School of Medicine · St Louis, United StatesNot yet recruiting→Recruiting
Oct 16, 2026
Secondary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameBiomarkers of agingbaseline, week 5, and week 30 → baseline
  • DescriptionBiomarkers of aging: how it is measured was reworded
Oct 16, 2026
Site contacts
Changed at 10 sites. See the sites
Show 10 sites
  • Stanford School of Medicine · Stanford, United StatesContact l•••@stanford.edu · •••5511→s•••@stanford.edu · •••8585Contact added (no phone or email listed)
  • Children's Hospital Colorado · Aurora, United StatesContact s•••@childrenscolorado.org · •••4599→A•••@childrenscolorado.org · •••8306
  • Emory University School of Medicine · Atlanta, United StatesContact K•••@choa.org→M•••@choa.org · •••7453
  • Washington University School of Medicine · St Louis, United StatesContact a•••@wustl.edu→a•••@wustl.edu · •••5642Contact added (no phone or email listed)
  • Icahn School of Medicine at Mount Sinai · New York, United StatesContact x•••@mssm.edu · •••7148→a•••@mssm.edu · •••0238
  • Columbia University Irving Medical Center · New York, United StatesContact m•••@cumc.columbia.edu · •••1562→n•••@cumc.columbia.edu · •••3785
  • Cincinnati Children's Hospital Medical Center · Cincinnati, United StatesContact P•••@cchmc.org · •••1523→E•••@cchmc.org · •••3350Contact added (no phone or email listed)
  • Children's Hospital of Philadelphia · Philadelphia, United StatesContact j•••@chop.edu→H•••@chop.edu · •••9271Contact added (no phone or email listed)
  • Children's Hospital of Pittsburgh · Pittsburgh, United StatesContact b•••@chp.edu→m•••@chp.edu · •••6762
  • Medical University of South Carolina · Charleston, United StatesContact g•••@musc.edu→h•••@musc.edu · •••3796
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Stanford School of Medicine · Stanford, United StatesNot yet recruiting→Recruiting
    • Washington University School of Medicine · St Louis, United StatesNot yet recruiting→Recruiting
    Secondary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameBiomarkers of agingbaseline, week 5, and week 30 → baseline
    • DescriptionBiomarkers of aging: how it is measured was reworded
    Site contacts Changed at 10 sites. See the sites
    Show 10 sites
    • Stanford School of Medicine · Stanford, United StatesContact l•••@stanford.edu · •••5511→s•••@stanford.edu · •••8585Contact added (no phone or email listed)
    • Children's Hospital Colorado · Aurora, United StatesContact s•••@childrenscolorado.org · •••4599→A•••@childrenscolorado.org · •••8306
    • Emory University School of Medicine · Atlanta, United StatesContact K•••@choa.org→M•••@choa.org · •••7453
    • Washington University School of Medicine · St Louis, United StatesContact a•••@wustl.edu→a•••@wustl.edu · •••5642Contact added (no phone or email listed)
    • Icahn School of Medicine at Mount Sinai · New York, United StatesContact x•••@mssm.edu · •••7148→a•••@mssm.edu · •••0238
    • Columbia University Irving Medical Center · New York, United StatesContact m•••@cumc.columbia.edu · •••1562→n•••@cumc.columbia.edu · •••3785
    • Cincinnati Children's Hospital Medical Center · Cincinnati, United StatesContact P•••@cchmc.org · •••1523→E•••@cchmc.org · •••3350Contact added (no phone or email listed)
    • Children's Hospital of Philadelphia · Philadelphia, United StatesContact j•••@chop.edu→H•••@chop.edu · •••9271Contact added (no phone or email listed)
    • Children's Hospital of Pittsburgh · Pittsburgh, United StatesContact b•••@chp.edu→m•••@chp.edu · •••6762
    • Medical University of South Carolina · Charleston, United StatesContact g•••@musc.edu→h•••@musc.edu · •••3796
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07525843
Lead sponsor
Carelon Research
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 20, 2026
Primary completion
Apr 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Jessica E Teng, MPH
Contact
jessica.teng@carelon.com
6179723047
Alliison Crosby-Thompson, MS
Contact
allison.crosby-thompson@carelon.com
6179723285
Melissa Cousino, PhD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion